PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
EBV positive tumor accounts for 8-9% of all gastric cancer (GC) patients. PD-1 antibody has
been proved as third line therapy for PD-L1 positive gastric cancer. Previous studies showed
that EBV(+) tumors exhibit high response to PD-1 antibody. In this phase II study, we will
investigate the efficacy and safety of PD-1 antibody in EBV positive metastatic GC patients.